Next Article in Journal
Challenging Autologous Breast Reconstruction in Low BMI Patients with Profunda Artery Perforator (PAP) Flap: Impact of Skin Island Design on Complication Rates and Long-Term Aesthetic Outcomes
Previous Article in Journal
Bilateral Sensorineural Hearing Loss in a Patient with Primary Ciliary Dyskinesia and Concomitant SH3TC2 Gene Mutation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Mitochondrial Dysfunction in the Development and Progression of Cardiometabolic Diseases: A Narrative Review

1
Diabetes Center, 2nd Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece
2
2nd Cardiology Department, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 15772 Athens, Greece
3
Endocrine Unit, 1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
4
3rd Department of Cardiology, “Sotiria” Thoracic Diseases Hospital of Athens, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Clin. Med. 2025, 14(11), 3706; https://doi.org/10.3390/jcm14113706
Submission received: 15 April 2025 / Revised: 19 May 2025 / Accepted: 23 May 2025 / Published: 25 May 2025
(This article belongs to the Section Cardiovascular Medicine)

Abstract

Mitochondria play a central role in energy metabolism and continuously adapt through dynamic processes such as fusion and fission. When the balance between these processes is disrupted, it can lead to mitochondrial dysfunction and increased oxidative stress, contributing to the development and progression of various cardiometabolic diseases (CMDs). Their role is crucial in diabetes mellitus (DM), since their dysfunction drives β-cell apoptosis, immune activation, and chronic inflammation through excessive ROS production, worsening endogenous insulin secretion. Moreover, sympathetic nervous system activation and altered dynamics, contribute to hypertension through oxidative stress, impaired mitophagy, endothelial dysfunction, and cardiomyocyte hypertrophy. Furthermore, the role of mitochondria is catalytic in endothelial dysfunction through excessive reactive oxygen species (ROS) production, disrupting the vascular tone, permeability, and apoptosis, while impairing antioxidant defense and promoting inflammatory processes. Mitochondrial oxidative stress, resulting from an imbalance between ROS/ Reactive nitrogen species (RNS) imbalance, promotes atherosclerotic alterations and oxidative modification of oxidizing low-density lipoprotein (LDL). Mitochondrial DNA (mtDNA), situated in close proximity to the inner mitochondrial membrane where ROS are generated, is particularly susceptible to oxidative damage. ROS activate redox-sensitive inflammatory signaling pathways, notably the nuclear factor kappa B (NF-κB) pathway, leading to the transcriptional upregulation of proinflammatory cytokines, chemokines, and adhesion molecules. This proinflammatory milieu promotes endothelial activation and monocyte recruitment, thereby perpetuating local inflammation and enhancing atherogenesis. Additionally, mitochondrial disruptions in heart failure promote further ischemic injury and excessive oxidative stress release and impair ATP production and Ca2⁺ dysregulation, contributing to cell death, fibrosis, and decreased cardiac performance. This narrative review aims to investigate the intricate relationship between mitochondrial dysfunction and CMDs.
Keywords: mitochondrial dysfunction; cardiovascular disease; metabolic syndrome; mitochondrial dynamics mitochondrial dysfunction; cardiovascular disease; metabolic syndrome; mitochondrial dynamics

Share and Cite

MDPI and ACS Style

Pliouta, L.; Lampsas, S.; Kountouri, A.; Korakas, E.; Thymis, J.; Kassi, E.; Oikonomou, E.; Ikonomidis, I.; Lambadiari, V. Mitochondrial Dysfunction in the Development and Progression of Cardiometabolic Diseases: A Narrative Review. J. Clin. Med. 2025, 14, 3706. https://doi.org/10.3390/jcm14113706

AMA Style

Pliouta L, Lampsas S, Kountouri A, Korakas E, Thymis J, Kassi E, Oikonomou E, Ikonomidis I, Lambadiari V. Mitochondrial Dysfunction in the Development and Progression of Cardiometabolic Diseases: A Narrative Review. Journal of Clinical Medicine. 2025; 14(11):3706. https://doi.org/10.3390/jcm14113706

Chicago/Turabian Style

Pliouta, Loukia, Stamatios Lampsas, Aikaterini Kountouri, Emmanouil Korakas, John Thymis, Eva Kassi, Evangelos Oikonomou, Ignatios Ikonomidis, and Vaia Lambadiari. 2025. "Mitochondrial Dysfunction in the Development and Progression of Cardiometabolic Diseases: A Narrative Review" Journal of Clinical Medicine 14, no. 11: 3706. https://doi.org/10.3390/jcm14113706

APA Style

Pliouta, L., Lampsas, S., Kountouri, A., Korakas, E., Thymis, J., Kassi, E., Oikonomou, E., Ikonomidis, I., & Lambadiari, V. (2025). Mitochondrial Dysfunction in the Development and Progression of Cardiometabolic Diseases: A Narrative Review. Journal of Clinical Medicine, 14(11), 3706. https://doi.org/10.3390/jcm14113706

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop